Copied
 
 
2022, EUR
06.06.2023
Bruttoresultat

-4.000

Primær drift

59.267'

Årets resultat

12.276'

Aktiver

131''

Kortfristede aktiver

3.000

Egenkapital

131''

Afkastningsgrad

45 %

Soliditetsgrad

100 %

Likviditetsgrad

18 %

Resultat
06.06.2023
Årsrapport
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Nettoomsætning1.513.706.0001.417.811.0000981.554.000
Bruttoresultat-4.000-5.00000
Resultat af primær drift59.267.00054.495.000-2.000-2.000
Indtægter af kapitalandele (tilknyttede og associerede) 0000
Finansielle indtægter6.267.00012.317.00000
Finansieringsomkostninger00-1.0000
Andre finansielle omkostninger-4.000-2.00000
Resultat før skat12.274.00018.514.00015.002.00019.005.000
Resultat12.276.00018.515.00015.003.00019.005.000
Forslag til udbytte0-2.750.000-2.750.000-8.360.000
Aktiver
06.06.2023
Årsrapport
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Kortfristede varebeholdninger309.607.000271.226.00000
Kortfristede tilgodehavender fra salg og tjenesteydelser 2.0002.0001.0000
Likvider1.0004.985.0001.0000
Kortfristede aktiver3.0002.0002.0000
Immaterielle aktiver og goodwill518.591.000541.329.00000
Finansielle anlægsaktiver130.938.000123.049.000106.239.00098.554.000
Materielle aktiver123.101.000109.757.00000
Langfristede aktiver130.938.000123.049.000106.239.00098.554.000
Aktiver130.941.000123.051.000106.241.00098.554.000
Aktiver
06.06.2023
Passiver
06.06.2023
Årsrapport
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Forslag til udbytte02.750.0002.750.0008.360.000
Egenkapital130.924.000123.041.000106.236.00098.552.000
Hensatte forpligtelser37.347.00068.151.00000
Langfristet gæld til banker560.103.000550.240.00000
Anden langfristet gæld0000
Leverandører af varer og tjenesteydelser86.860.000116.466.00000
Kortfristede forpligtelser17.00010.0005.0002.000
Gældsforpligtelser17.00010.0005.0002.000
Forpligtelser17.00010.0005.0002.000
Passiver130.941.000123.051.000106.241.00098.554.000
Passiver
06.06.2023
Nøgletal
06.06.2023
Årsrapport
2022
06.06.2023
2021
05.07.2022
2020
09.07.2021
2019
24.06.2020
Afkastningsgrad 45,3 %44,3 %0,0 %0,0 %
Dækningsgrad 0,0 %0,0 %Na.Na.
Resultatgrad 0,8 %1,3 %Na.1,9 %
Varelagerets omsætningshastighed 4,9 5,2 Na.Na.
Egenkapitals-forretning 9,4 %15,0 %14,1 %19,3 %
Payout-ratio Na.14,9 %18,3 %44,0 %
Gældsdæknings-nøgletal Na.Na.-200,0 %Na.
Soliditestgrad 100,0 %100,0 %100,0 %100,0 %
Likviditetsgrad 17,6 %20,0 %40,0 %Na.
Resultat
06.06.2023
Gæld
06.06.2023
Årsrapport
06.06.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 06.06.2023)
Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act ​governing reporting class C enterprises (large). The accounting policies applied to these consolidated financial statements and parent financial statements are consistent with those applied last year. The annual report is presented in EUR.
Oplysning om pantsætninger og sikkerhedsstillelser:20 Assets charged and collateralGroup companies have provided inventories EUR 25.0 million as security for debt to the Group's banks and credit institutions. In addition, pledged unlisted shares in certain Group companies with a total carrying amount of EUR 359.8 million at 31 December 2022 have been provided as security for bank debt and debt to credit institutions. Mortgage deeds and letter of indemnity have been issued as security for credit institutions with a nominal amount of EUR 52.6 million. The actual liability on the balance sheet date amounts to EUR 19.5 million and the carrying amount of plegded properties amounts to EUR 52 million at 31 December 2022.
Beretning
06.06.2023
Dato for ledelsens godkendelse af årsrapporten:2023-06-05
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Executive Board has today considered and approved the annual report of HBS Capital ApS for the financial year 01. 01. 2022 - 31. 12. 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesHBS Capital ApS is a holding company established and ultimately owned by the Bøgh-Sørensen family. The Group’s primary business activity is being an ambitious operator in the European market for pharmaceuticals through the investment in Orifarm Group A/S, which is the largest supplier of parallel imported pharmaceuticals in Europe, and a producer and seller of well-known brands as well as generic pharmaceuticals. Secondly the HBS Capital Group invests across a broad range of asset classes including Private Equity, Real Estate, Investment cars and other financial assets both public and private, through the ownership of Habico Invest A/S. Orifarm Group Orifarm Group is a dynamic international player in the healthcare business. Our vision is to be no. 1 in making healthcare a better deal. Every day, we strive to make high quality pharmaceuticals at affordable prices available to end users by manufacturing, commercializing, and trading products. The company's purpose is to provide as many people as possible with access to cheaper quality medicine. We supply a wide range of high-quality pharmaceuticals across several therapeutic areas and stages of illness. Our portfolio covers pharmaceuticals for primary as well as secondary care by specialists, over the counter (OTC), and consumer healthcare products. It is our mission to challenge the market and make affordable, high-quality healthcare accessible. We want to create competition and provide important savings for society and to ensure better value for money for consumers while maintaining a high quality in our products. We challenge the market in all corners of our business – from selling original pharmaceuticals at lower prices to developing competitive pharmaceuticals and preparations. Orifarm Group consists of two main business areas: Orifarm Health Access and Orifarm Healthcare. Orifarm Health Access The main activity in Orifarm Health Access is parallel import of pharmaceuticals. Pharmaceuticals are bought in EU/EEA members with low prices and then re-packed, imported and sold in other EU/EEA markets with higher prices. Orifarm Health Access is also active in Clinical Trials Supply and sales of Unlicensed pharmaceuticals. Orifarm Healthcare The Orifarm Healthcare portfolio is structured in four Strategic Business Areas and include strong brands within OTC, Consumer Healthcare and Specialty Pharma (Rx). In addition, a diverse portfolio of Niche Generics. The Healthcare Portfolio operates across growing Health Areas such as Cough & Cold, Vitamins & Food Supplements, Immune Boost, Gastro, Allergy and Mood. Further, the portfolio supports many patients across the different stage of illness from prevention to alleviation of symptoms to treatment. High-quality medication at affordable prices and access to patients is of highest priority to Orifarm and the Healthcare Portfolio is available in pharmacies (physical outlets and online pharmacies), primary care and in some markets retail and drug stores. Habico Invest Habico Invest A/S invests across a broad range of asset classes including Private Equity, Real Estate, Investment cars and other financial assets both public and private.
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK